Arena Pharmaceuticals Inc to consider Key Opinion Leader Event on Pulmonary Arterial Hypertension (PAH)
Llamada en conferencia Arena Pharmaceuticals Inc
Arena Pharmaceuticals Inc Conference call or earnings call will be held on 25-may-2017 via an 800 number (toll-free). During the earnings conference call's session Arena Pharmaceuticals Inc will provide updated information and financial status.
Conference call is also referred to as: teleconference call or audio conference bridge. Conferencing service is provided in house or as cloud based teleconference service.
In order to join the audio conferencing dial conference bridge and key in the PIN code, Contact Arena Pharmaceuticals Inc for this information
Schedule a teleconference with QCONF and get 5 free calls with our conference service.
We are embracing the challenge of improving health by seeking to bring innovative medicines targeting G protein-coupled receptors, or GPCRs, to patients. Our focus is discovering, developing and commercializing drugs to address unmet medical needs, and we have an internally discovered drug, lorcaserin, that is being marketed and a pipeline of novel drug candidates that we intend to advance. Lorcaserin, our first and only approved drug, is approved for marketing in the United States and South Korea for the indication of weight management, and is being commercialized under the brand name BELVIQ® (which is pronounced as "BEL-VEEK"). BELVIQ was made available by prescription in the United States in June 2013 and in South Korea in February 2015, and there are pending applications for the regulatory approval of BELVIQ for marketing in a number of additional territories.Leer más Llamada en conferencia